Aclaris Therapeutics ACRS Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aclaris Therapeutics's increase (decrease) in contract liabilities and current deferred income?
- Aclaris Therapeutics (ACRS) reported increase (decrease) in contract liabilities and current deferred income of -$854K in Q1 2026.
- How has Aclaris Therapeutics's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- Aclaris Therapeutics's increase (decrease) in contract liabilities and current deferred income decreased by 2.5% year-over-year, from -$833K to -$854K.